|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Smith HO, Tiffany MF, Qualls CR and Key
CR: The rising incidence of adenocarcinoma relative to squamous
cell carcinoma of the uterine cervix in the United States-a 24-year
population-based study. Gynecol Oncol. 78:97–105. 2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Adegoke O, Kulasingam S and Virnig B:
Cervical cancer trends in the United States: A 35-year
population-based analysis. J Womens Health (Larchmt). 21:1031–1037.
2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
International Agency for Research on
Cancer (IARC): Female Genital Tumours. In: WHO Classification of
Tumours. Vol 4. 5th edition. IARC, Lyon, pp374-375, 2020.
|
|
5
|
Takatsu A, Shiozawa T, Miyamoto T,
Kurosawa K, Kashima H, Yamada T, Kaku T, Mikami Y, Kiyokawa T,
Tsuda H, et al: Preoperative differential diagnosis of minimal
deviation adenocarcinoma and lobular endocervical glandular
hyperplasia of the uterine cervix: A multicenter study of
clinicopathology and magnetic resonance imaging findings. Int J
Gynecol Cancer. 21:1287–1296. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kido A, Mikami Y, Koyama T, Kataoka M,
Shitano F, Konishi I and Togashi K: Magnetic resonance appearance
of gastric-type adenocarcinoma of the uterine cervix in comparison
with that of usual-type endocervical adenocarcinoma: A pitfall of
newly described unusual subtype of endocervical adenocarcinoma. Int
J Gynecol Cancer. 24:1474–1479. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nishio S, Mikami Y, Tokunaga H, Yaegashi
N, Satoh T, Saito M, Okamoto A, Kasamatsu T, Miyamoto T, Shiozawa
T, et al: Analysis of gastric-type mucinous carcinoma of the
uterine cervix-An aggressive tumor with a poor prognosis: A
multi-institutional study. Gynecol Oncol. 153:13–19.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Karamurzin YS, Kiyokawa T, Parkash V,
Jotwani AR, Patel P, Pike MC, Soslow RA and Park KJ: Gastric-type
endocervical adenocarcinoma: An aggressive tumor with unusual
metastatic patterns and poor prognosis. Am J Surg Pathol.
39:1449–1457. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jung H, Bae GE, Kim HM and Kim HS:
Clinicopathological and molecular differences between gastric-type
mucinous carcinoma and usual-type endocervical adenocarcinoma of
the uterine cervix. Cancer Genomics Proteomics. 17:627–641.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kojima A, Mikami Y, Sudo T, Yamaguchi S,
Kusanagi Y, Ito M and Nishimura R: Gastric morphology and
immunophenotype predict poor outcome in mucinous adenocarcinoma of
the uterine cervix. Am J Surg Pathol. 31:664–672. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Frenel JS, Le Tourneau C, O'Neil B, Ott
PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas
S, Saraf S, et al: Safety and efficacy of pembrolizumab in
advanced, programmed death ligand 1-positive cervical cancer:
Results from the phase Ib KEYNOTE-028 trial. J Clin Oncol.
35:4035–4041. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chung HC, Ros W, Delord JP, Perets R,
Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L,
Zeigenfuss S, et al: Efficacy and safety of pembrolizumab in
previously treated advanced cervical cancer: Results from the phase
II KEYNOTE-158 study. J Clin Oncol. 37:1470–1478. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Monk BJ, Colombo N, Tewari KS, Dubot C,
Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş
M, et al: First-Line pembrolizumab + chemotherapy versus placebo +
chemotherapy for persistent, recurrent, or metastatic cervical
cancer: Final overall survival results of KEYNOTE-826. J Clin
Oncol. 41:5505–5511. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Colombo N, Dubot C, Lorusso D, Caceres MV,
Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Usta EH, Yañez
E, et al: Pembrolizumab for persistent, recurrent, or metastatic
cervical cancer. N Engl J Med. 385:1856–1867. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Abu-Rustum NR, Yashar CM, Arend R, Barber
E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA,
et al: NCCN guidelines® insights: Cervical cancer,
version 1.2024. J Natl Compr Canc Netw. 21:1224–1233.
2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lorusso D, Xiang Y, Hasegawa K, Scambia G,
Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, de Santana
Gomes AJ, et al: Pembrolizumab or placebo with chemoradiotherapy
followed by pembrolizumab or placebo for newly diagnosed,
high-risk, locally advanced cervical cancer
(ENGOT-cx11/GOG-3047/KEYNOTE-A18): A randomised, double-blind,
phase 3 clinical trial. Lancet. 403:1341–1350. 2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen L, Lucas E, Zhang X, Liu Q, Zhuang Y,
Lin W, Chen H and Zhou F: Programmed death-ligand 1 expression in
human papillomavirus-independent cervical adenocarcinoma and its
prognostic significance. Histopathology. 80:338–347.
2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sun Y, Zhou X, Lucas E, Chen L, Zhang H,
Chen H and Zhou F: Expression of B7-H3 and TIM-3 in gastric-type
endocervical adenocarcinoma: Prevalence, association with PD-L1
expression, and prognostic significance. J Pathol Clin Res.
10(e345)2024.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Ehmann S, Sassine D, Straubhar AM, Praiss
AM, Aghajanian C, Alektiar KM, Broach V, Cadoo KA, Jewell EL,
Boroujeni AM, et al: Gastric-type adenocarcinoma of the cervix:
Clinical outcomes and genomic drivers. Gynecol Oncol. 167:458–466.
2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang S, Zhou X, Niu S, Chen L, Zhang H,
Chen H and Zhou F: Assessment of HER2 in gastric-type endocervical
adenocarcinoma and its prognostic significance. Mod Pathol.
36(100148)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shi H, Shao Y, Lu W and Lu B: An analysis
of HER2 amplification in cervical adenocarcinoma: Correlation with
clinical outcomes and the international endocervical adenocarcinoma
criteria and classification. J Pathol Clin Res. 7:86–95.
2021.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Fader AN, Roque DM, Siegel E, Buza N, Hui
P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM,
et al: Randomized phase II trial of carboplatin-paclitaxel versus
carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas
that overexpress human epidermal growth factor receptor 2/neu. J
Clin Oncol. 36:2044–2051. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fader AN, Roque DM, Siegel E, Buza N, Hui
P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM,
et al: Randomized phase II trial of carboplatin-paclitaxel compared
with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV)
or recurrent uterine serous carcinomas that overexpress Her2/Neu
(NCT01367002): Updated overall survival analysis. Clin Cancer Res.
26:3928–3935. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yang J, Peng Y, Ding Y, Liu Y, Wang Y, Liu
Y and Liu C: The clinicopathological and molecular characteristics
of endocervical gastric-type adenocarcinoma and the use of
claudin18.2 as a potential therapeutic target. Mod Pathol.
37(100569)2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Niimi T, Nagashima K, Ward JM, Minoo P,
Zimonjic DB, Popescu NC and Kimura S: claudin-18, a novel
downstream target gene for the T/EBP/NKX2.1 homeodomain
transcription factor, encodes lung- and stomach-specific isoforms
through alternative splicing. Mol Cell Biol. 21:7380–7390.
2001.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sahin U, Koslowski M, Dhaene K, Usener D,
Brandenburg G, Seitz G, Huber C and Türeci O: Claudin-18 splice
variant 2 is a pan-cancer target suitable for therapeutic antibody
development. Clin Cancer Res. 14:7624–7634. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Qi C, Liu C, Gong J, Liu D, Wang X, Zhang
P, Qin Y, Ge S, Zhang M, Peng Z, et al: Claudin18.2-specific CAR T
cells in gastrointestinal cancers: Phase 1 trial final results. Nat
Med. 30:2224–2234. 2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liang Z, Liu L, Li W, Lai H, Li L, Wu J,
Zhang H and Fang C: Efficacy and safety of zolbetuximab for
first-line treatment of advanced Claudin 18. 2-positive gastric or
gastro-esophageal junction adenocarcinoma: A systematic review and
meta-analysis of randomized controlled trials. Front Oncol.
13(1258347)2023.PubMed/NCBI View Article : Google Scholar
|
